Posted by Michael Wonder on 22 May 2024
Durect Corporation receives FDA breakthrough therapy designation for larsucosterol in alcohol-associated hepatitis
21 May 2024 - Durect plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial.
Durect Corporation today announced that the US FDA has granted breakthrough therapy designation to larsucosterol for the treatment of patients with severe alcohol-associated hepatitis.
